Skip to main content
Log in

A Population Pharmacokinetic–Pharmacodynamic Analysis of Repeated Measures Time-to-Event Pharmacodynamic Responses: The Antiemetic Effect of Ondansetron

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

This paper presents and illustrates methodology for specifying, estimating, and evaluating a predictive model for repeated measures time-to-event responses. The illustrative example specifies a model of the antiemetic effect vs. concentration relationship for the 5-HT 3 antagonist ondansetron in the human ipecac model for emesis. A key part of this model is a time-dependent log hazard function for emesis that is increased by ipecac administration and decreased by ondansetron concentration. The model is fit using an approximate maximum likelihood method. The data consist of the time free of emeses and, for those individuals with emetic episodes, the time(s) of the episode(s). Model evaluation is accomplished using residual plots adapted to time-to-event data and a “posterior predictive check” wherein observed data statistics are compared to those obtained from data simulated from the fitted model. The ondansetron concentration required to obtain a 50% reduction in the hazard of emesis is estimated to be 1.4±0.2 ng/ml, and the rate constant for elimination of ipecac-induced hazard is 1.5±0.2hr −1 .

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. N. H. G. Holford, J. P. R. Monteleone, H. C. Ko, and C. C. Peck. Ann. Rev. Pharmacol. Toxicol. 40:209–234 (2000).

    Article  CAS  Google Scholar 

  2. J. Dingemanse, M. Danhof, and D. D. Breimer. Pharmacokinetic-pharmacodynamic modelling of CNS drug effects. Pharmacol. Ther. 38:1–52 (1988).

    Article  CAS  PubMed  Google Scholar 

  3. J. W. Blue and W. A. Coburn. Efficacy measures: surrogates or clinical outcomes? J. Clin. Pharmacol. 36:767–770 (1996).

    Article  CAS  PubMed  Google Scholar 

  4. M. E. Ausems, C. C. Hug, Jr., D. R. Stanski, and A. G. Burm. Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. Anesthesiology 65:362–373 (1986).

    Article  CAS  PubMed  Google Scholar 

  5. L. B. Sheiner. A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clin. Pharmacol. Ther. 56:309–322 (1994).

    Article  CAS  PubMed  Google Scholar 

  6. J. W. Mandema and D. R. Stanski. Population pharmacodynamic model for ketorolac analgesia. Clin. Pharmacol. Ther. 60:619–635 (1996).

    Article  CAS  PubMed  Google Scholar 

  7. L. B. Sheiner, S. L. Beal, and A. Dunne. Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials. J. Am. Statist. Assoc. 92:1235–1244 (1997).

    Article  Google Scholar 

  8. D. J. Sargent. A general framework for random effects survival analysis in the Cox proportional hazards setting. Biometrics 54:1486–1497 (1998).

    Article  CAS  PubMed  Google Scholar 

  9. N. Minton, R. Swift, C. Lawlor, T. Mant, and J. Henry. Ipecacuanha-induced emesis: A human model for testing antiemetic drug activity. Clin. Pharmacol. Ther. 54:53–57 (1993).

    Article  CAS  PubMed  Google Scholar 

  10. P. V. Colthup, C. C. Felgate, J. L. Palmer, and N. L. Scully. Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly. J. Pharm. Sci. 80:868–871 (1991).

    Article  CAS  PubMed  Google Scholar 

  11. S. A. Wring, R. M. Rooney, C. P. Goddard, I. Waterhouse, and W. N. Jenner. A sensitive radioimmunoassay, combined with solid phase extraction, for the subnanogram per ml determination of ondansetron in human plasma. J. Pharm. Biomed. Anal. 12:361–371 (1994).

    Article  CAS  PubMed  Google Scholar 

  12. S. L. Beal and L. B. Sheiner. NONMEM User's Guides. UCSF: NONMEM Project Group, 1992.

  13. C. Veyrat-Follet, E. Fuseau, R. Farinotti, and J. Palmer. Population pharmacokinetics of ondansetron: Model building approaches. J. Pharmacokin. Biopharm. 2000: submitted.

  14. S. Ross. Stochastic Processes, Wiley, New York, 1983.

    Google Scholar 

  15. J. D. Kalbfleisch and R. L. Prentice. The Statistical Analysis of Failure Time Data, Wiley, New York (1980).

    Google Scholar 

  16. T. M. Therneau, P. M. Grambsch, and T. R. Fleming. Martingale-based residuals for survival models. Biometrika 77:147–160 (1990).

    Article  Google Scholar 

  17. D. Collett, Modeling Survival Data in Medical Research, Chapman and Hall, London, 1994.

    Book  Google Scholar 

  18. A. Gelman, J. B. Carlin, H. S. Stern, and D. B. Rubin (eds.). Bayesian Data Analysis, Chapman and Hall, London, 1995.

    Google Scholar 

  19. A. Gelman, X. L. Meng, and H. Stern. Posterior predictive assessment of model fitness via realized discrepancies. Stat. Sinica 6:733–807 (1996).

    Google Scholar 

  20. R. A. Maller and X. Zhou (eds.). Survival Analysis with Long-Term Survivors, Wiley, New York, 1996.

    Google Scholar 

  21. P. O. Maitre, M. Bührer, D. Thomson, and D. R. Stanski. A three-step approach combining Bayesian regression and NONMEM population analysis: Application to midazolam. J. Pharmacokin. Biopharm. 19:377–384 (1991).

    Article  CAS  Google Scholar 

  22. J. W. Mandema, D. Verotta, and L. B. Sheiner. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J. Pharmacokin. Biopharm. 20:511–528 (1992).

    Article  CAS  Google Scholar 

  23. D. R. Cox and E. J. Snell. A general definition of residuals (with discussion). J. Roy. Statist. Soc. A 30:248–275 (1968).

    Google Scholar 

  24. T. R. Fleming and D. P. Harrington (eds.). Counting Processes and Survival Analysis, Wiley, New York, 1991.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cox, E.H., Veyrat-Follet, C., Beal, S.L. et al. A Population Pharmacokinetic–Pharmacodynamic Analysis of Repeated Measures Time-to-Event Pharmacodynamic Responses: The Antiemetic Effect of Ondansetron. J Pharmacokinet Pharmacodyn 27, 625–644 (1999). https://doi.org/10.1023/A:1020930626404

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1020930626404

Navigation